Orion is a Finnish pharmaceutical company that develops, manufactures and markets prescription drugs for humans and animals. Its portfolio is strong in central nervous system, oncology and critical-care therapies, with products sold under its own brands and through global licensing partners. Manufacturing and R&D are centered in Finland, while commercial reach extends across Europe and selected international markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 354.6 | — | 61.3 | — |
| Q2 2025 | 416.5 | — | 82.5 | — |
| Q4 2025 | 695.3 | — | 260.5 | — |
| Q1 2026 | 417.7 | 17.8% | 90.4 | 47.5% |
| Q2 2026 | 521.6 | 25.2% | 140.2 | 69.9% |
All markets — KeepWinning global stock screener
Other companies on Helsinki: SSAB AB (publ) (SSABBH), SSAB AB (publ) (SSABAH), Kesko Oyj (KESKOB), Kesko Oyj (KESKOA), Stora Enso Oyj (STEAV), Stora Enso Oyj (STERV)